Журнал "Почки" том 9, №3

Íàñòàíîâè / Guidelines
1 2 3
Rituximab –
Statins: creatinine kinase (CK) –
Prolonged glucocorticoid therapy
Renal ultrasound: renal echogenicity and size of kidneys
Imaging
–
Conditional
End of the Table 2
CD19 B cell count: baseline,
1 month after the
first dose (nadir), every
1–3 months until B cell
recovery
If on statins, every 6
months
Ophthalmological examination
for cataract and intraocular
pressure. Bone mineral
density by lumbar DEXA
At presentation (mandatory
prerenal biopsy)
Ultrasound of abdomen & pleural space (ascites, effusions, thrombosis) Аs appropriate
Cardiac ultrasound (left ventricular mass, effusions)
Chest X-ray
X-ray of the left wrist (bone age assessment in children aged > 5 years, mineralization)
Histopathology
Renal biopsy
Dietary assessment
Dietician review and advice by a dietician regarding salt, potassium, caloric
and protein intake
Assessment for extrarenal involvement
Depending on underlying disease and clinically evident extrarenal features:
— Brain MRI (e.g., microcephaly, psychomotor delay, mental retardation,
myoclonic epilepsy, tremor, ataxia, hypotonia)
— Interdisciplinary evaluation by Ophthalmology (e.g., microcoria, cataract,
glaucoma, optic atrophy, keratoconus, macular spots, lenticonus, nystagmus)
— Cardiology (e.g., congenital heart defects)
— Endocrinology (ambiguous genitalia, delayed puberty, primary amenorrhea,
pesudohermaphroditism, diabetes mellitus)
— Dermatology (e.g., epidermolysis bullosa)
— Orthopedics (absent or hypoplastic patella, spondyloepiphyseal dysplasia)
— Immunology (T cell immunodeficiency)
— Hematology (thrombocytopenia with large platelets, Döhle bodies)
— Audiology (sensorineural hearing loss)
Optional
If indicated
Every 12 months in hypertensive
patients or in
case of severe edema
If indicated
Every 12 months or as
appropriate
See text: at diagnosis, and
subsequently if indicated:
in case of unexplained
drop in eGFR, unexplained
increase in proteinuria, to
rule out and/or to monitor
CNI nephrotoxicity during
prolonged (< 2 years)
treatment
Every 3 months (more
frequently in infants, malnourished
patients, and
patients with CKD stage
4–5)
If indicated
ALP — alkaline phosphatase; PTH — parathyroid hormone; CNI — calcineurin inhibitor; CsA — cyclosporine
A; BP — blood pressure; MMF — mycophenolate mofetil; a — аnthropometric data should be compared
with updated national or international (WHO charts [20]) standards; b — eGFR (ml/min/1.73 m 2 ) — k × height
(cm)/plasma creatinine (mg/dl); where k is a constant = 0.413. In malnourished or obese patients cystatin-based
equations should be used [21]; c — аccording to Gellerman et al. [22].
Òîì 9, ¹ 3, 2020
www.mif-ua.com, http://kidneys.zaslavsky.com.ua 77